Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy.

Tanabe K, Tamura Y, Lanaspa MA, Miyazaki M, Suzuki N, Sato W, Maeshima Y, Schreiner GF, Villarreal FJ, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1264-74. doi: 10.1152/ajprenal.00227.2012. Epub 2012 Aug 29.

2.

Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages.

Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 Aug 1;303(3):F339-49. doi: 10.1152/ajprenal.00158.2012. Epub 2012 May 23.

3.

Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 May 1;302(9):F1151-60. doi: 10.1152/ajprenal.00596.2011. Epub 2012 Feb 15.

4.

Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS.

Anticancer Res. 2007 Nov-Dec;27(6B):4149-57. Erratum in: Anticancer Res. 2008 Jan-Feb;28(1b):567, 4152-3.

5.

Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA.

J Am Coll Cardiol. 2007 Mar 13;49(10):1071-8. Epub 2007 Feb 26.

6.

Improvement of human islet cryopreservation by a p38 MAPK inhibitor.

Omori K, Valiente L, Orr C, Rawson J, Ferreri K, Todorov I, Al-Abdullah IH, Medicherla S, Potter AA, Schreiner GF, Kandeel F, Mullen Y.

Am J Transplant. 2007 May;7(5):1224-32. Epub 2007 Feb 27.

7.

Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension.

Long DA, Mu W, Price KL, Roncal C, Schreiner GF, Woolf AS, Johnson RJ.

Am J Physiol Renal Physiol. 2006 Dec;291(6):F1248-54. Epub 2006 Jun 27.

8.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
9.

Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.

Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF.

J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. Epub 2006 Apr 7.

PMID:
16603672
10.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.

Exp Cell Res. 2006 Jun 10;312(10):1909-23. Epub 2006 Apr 4.

PMID:
16600214
11.

Inhibition of p38 mitogen-activated protein kinase protects human islets from cryoinjury and improves the yield, viability, and quality of frozen-thawed islets.

Omori K, Valiente L, Orr C, Rawson J, Ferreri K, Todorov I, Medicherla S, Protter AA, Schreiner GF, Riggs AD, Kandeel F, Mullen Y.

Transplant Proc. 2005 Oct;37(8):3422-3.

PMID:
16298615
12.

Affymetrix oligonucleotide analysis of gene expression in the injured heart.

Yanagawa B, Taylor L, Deisher TA, Ng R, Schreiner GF, Triche TJ, Yang D, McManus BM.

Methods Mol Med. 2005;112:305-20. Review.

PMID:
16010026
13.

Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts.

Nakagawa T, Lan HY, Glushakova O, Zhu HJ, Kang DH, Schreiner GF, Böttinger EP, Johnson RJ, Sautin YY.

J Am Soc Nephrol. 2005 Apr;16(4):899-904. Epub 2005 Feb 16.

14.

TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways.

Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Böttinger EP, Chen Y, Zhu HJ, Kang DH, Schreiner GF, Lan HY, Johnson RJ.

Kidney Int. 2004 Aug;66(2):605-13.

15.

Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells.

Nakagawa T, Lan HY, Zhu HJ, Kang DH, Schreiner GF, Johnson RJ.

Am J Physiol Renal Physiol. 2004 Oct;287(4):F658-64. Epub 2004 Jun 8.

16.

Increased oxidative stress following acute and chronic high altitude exposure.

Jefferson JA, Simoni J, Escudero E, Hurtado ME, Swenson ER, Wesson DE, Schreiner GF, Schoene RB, Johnson RJ, Hurtado A.

High Alt Med Biol. 2004 Spring;5(1):61-9.

PMID:
15072717
17.

The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis.

Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ.

J Am Soc Nephrol. 2004 Feb;15(2):370-9.

18.

Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway.

Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ.

Am J Pathol. 2004 Feb;164(2):477-85.

19.

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA.

Circ Res. 2004 Mar 5;94(4):453-61. Epub 2004 Jan 15.

PMID:
14726474
20.

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.

Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, Xu YJ, Laney M, Liu DY, Schreiner GF, Lewicki JA, Dugar S.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3087-90.

PMID:
12941340
21.

A single pathway for the development of essential hypertension.

Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodríguez-Iturbe B, Johnson RJ.

Cardiol Rev. 2003 Jul-Aug;11(4):180-96. Review. No abstract available.

PMID:
12852795
22.

Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue.

Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe SR, Csikari MM, Fischer D, Schreiner GF, Brandenburger GH, Villanueva FS.

Circulation. 2003 Jul 8;108(1):97-103. Epub 2003 Jun 23.

PMID:
12821549
23.

Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis.

Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ.

J Am Soc Nephrol. 2003 Feb;14(2):338-51.

24.

Hypertension: a microvascular and tubulointerstitial disease.

Johnson RJ, Rodríguez-Iturbe B, Schreiner GF, Herrera-Acosta J.

J Hypertens Suppl. 2002 Jun;20(3):S1-7. Review.

PMID:
12184051
25.

Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia.

Jefferson JA, Escudero E, Hurtado ME, Kelly JP, Swenson ER, Wener MH, Burnier M, Maillard M, Schreiner GF, Schoene RB, Hurtado A, Johnson RJ.

Am J Kidney Dis. 2002 Jun;39(6):1135-42.

PMID:
12046023
26.

B-type natriuretic peptide for the treatment of congestive heart failure.

Schreiner GF, Protter AA.

Curr Opin Pharmacol. 2002 Apr;2(2):142-7. Review.

PMID:
11950624
27.

Subtle acquired renal injury as a mechanism of salt-sensitive hypertension.

Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B.

N Engl J Med. 2002 Mar 21;346(12):913-23. Review. No abstract available.

PMID:
11907292
28.

Role of the microvascular endothelium in progressive renal disease.

Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ.

J Am Soc Nephrol. 2002 Mar;13(3):806-16. Review.

29.

Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels.

Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, Prchal J, Schreiner GF, Schoene RB, Hurtado A, Johnson RJ.

Lancet. 2002 Feb 2;359(9304):407-8.

PMID:
11844517
30.

Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121.

Villanueva FS, Abraham JA, Schreiner GF, Csikari M, Fischer D, Mills JD, Schellenberger U, Koci BJ, Lee JS.

Circulation. 2002 Feb 12;105(6):759-65.

PMID:
11839634
31.
32.

Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.

Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, Johnson RJ, Schreiner GF.

Kidney Int. 2001 Oct;60(4):1297-308.

33.
34.

Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.

Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ.

J Am Soc Nephrol. 2001 Jul;12(7):1434-47.

35.

Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor.

Kang DH, Kim YG, Andoh TF, Gordon KL, Suga S, Mazzali M, Jefferson JA, Hughes J, Bennett W, Schreiner GF, Johnson RJ.

Am J Physiol Renal Physiol. 2001 Apr;280(4):F727-36.

36.

Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.

Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, Johnson RJ.

Am J Kidney Dis. 2001 Mar;37(3):601-11.

PMID:
11228186
37.

Insulin-like growth factor-binding protein-3 induces fetalization in neonatal rat cardiomyocytes.

Henson M, Damm D, Lam A, Garrard LJ, White T, Abraham JA, Schreiner GF, Stanton LW, Joly AH.

DNA Cell Biol. 2000 Dec;19(12):757-63.

PMID:
11177573
38.

Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.

Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ.

Kidney Int. 2000 Dec;58(6):2390-9.

39.

CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis.

Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH.

J Mol Cell Cardiol. 2000 Oct;32(10):1805-19.

PMID:
11013125
40.

Altered patterns of gene expression in response to myocardial infarction.

Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, Zheng Q, Protter AA, Schreiner GF, White RT.

Circ Res. 2000 May 12;86(9):939-45.

PMID:
10807865
41.

Neutral lipid from proteinuric rat urine is a novel inhibitor of the red blood cell calcium pump.

Lindner A, Hinds TR, Joly A, Schreiner GF.

J Am Soc Nephrol. 1999 Jun;10(6):1170-8.

42.

Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist.

Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L.

J Am Soc Nephrol. 1999 Apr;10(4):714-20.

43.

CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity.

Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP.

J Pharmacol Exp Ther. 1998 Sep;286(3):1191-6.

PMID:
9732378
44.

Immune modulation of cardiac cell function.

Schreiner GF.

Trans Am Clin Climatol Assoc. 1998;109:39-49; discussion 49-50. Review. No abstract available.

45.

Natriuretic effect of adenosine A1-receptor blockade in rats.

Oberbauer R, Schreiner GF, Meyer TW.

Nephrol Dial Transplant. 1998 Apr;13(4):900-3.

PMID:
9568847
46.
47.

Evidence for inflammatory and secretagogue lipids in cyst fluids from patients with autosomal dominant polycystic kidney disease.

Grantham JJ, Schreiner GF, Rome L, Grenz L, Joly A.

Proc Assoc Am Physicians. 1997 Jul;109(4):397-408.

PMID:
9220537
48.

In vivo suppression of the renal Na+/Pi cotransporter by antisense oligonucleotides.

Oberbauer R, Schreiner GF, Biber J, Murer H, Meyer TW.

Proc Natl Acad Sci U S A. 1996 May 14;93(10):4903-6.

49.

Antisense and the kidney.

Oberbauer R, Murer H, Schreiner GF, Meyer TW.

Kidney Blood Press Res. 1996;19(5):221-4. Review.

50.

Renal uptake of an 18-mer phosphorothioate oligonucleotide.

Oberbauer R, Schreiner GF, Meyer TW.

Kidney Int. 1995 Oct;48(4):1226-32.

Supplemental Content

Loading ...
Support Center